2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-169690
    Casein kinase 1δ-IN-20 757224-44-5 98%
    Casein kinase 1δ-IN-20 (compound 427) is a potent casein kinase 1δ inhibitor. Casein kinase 1δ-IN-20 can be used in the study of neurodegenerative diseases such as Alzheimer's disease.
    Casein kinase 1δ-IN-20
  • HY-169692
    Casein kinase 1δ-IN-21 782457-22-1 98%
    Casein kinase 1δ-IN-21 (compound 501) is a potent casein kinase 1δ inhibitor. Casein kinase 1δ-IN-21 can be used in the study of neurodegenerative diseases such as Alzheimer's disease.
    Casein kinase 1δ-IN-21
  • HY-169701
    Casein kinase 1δ-IN-22 756849-12-4 98%
    Casein kinase 1δ-IN-22 (compound 484) is a potent casein kinase 1δ inhibitor. Casein kinase 1δ-IN-22 can be used in the study of neurodegenerative diseases such as Alzheimer's disease.
    Casein kinase 1δ-IN-22
  • HY-169702
    Casein kinase 1δ-IN-23 729579-66-2 98%
    Casein kinase 1δ-IN-23 (compound 423) is a potent casein kinase 1δ inhibitor. Casein kinase 1δ-IN-22 can be used in the study of neurodegenerative diseases such as Alzheimer's disease.
    Casein kinase 1δ-IN-23
  • HY-169704
    Ogerin analogue 1 1125453-08-8 98%
    Ogerin analogue 1 (compound 20) is a structural analog of Ogerin (HY-110279). Ogerin analogue 1 is generally used as a negative control.
    Ogerin analogue 1
  • HY-169705
    Casein kinase 1δ-IN-24 326034-30-4 98%
    Casein kinase 1δ-IN-24 (compound 489) is a potent casein kinase 1δ inhibitor. Casein kinase 1δ-IN-24 can be used in the study of neurodegenerative diseases such as Alzheimer's disease.
    Casein kinase 1δ-IN-24
  • HY-169706
    Casein kinase 1δ-IN-25 753468-25-6 98%
    Casein kinase 1δ-IN-25 (compound 487) is a potent casein kinase 1δ inhibitor. Casein kinase 1δ-IN-25 can be used in the study of neurodegenerative diseases such as Alzheimer's disease.
    Casein kinase 1δ-IN-25
  • HY-169709
    Casein kinase 1δ-IN-26 756857-71-3 98%
    Casein kinase 1δ-IN-26 (compound 505) is a potent casein kinase 1δ inhibitor. Casein kinase 1δ-IN-26 can be used in the study of neurodegenerative diseases such as Alzheimer's disease.
    Casein kinase 1δ-IN-26
  • HY-169719
    CK1δ-IN-6 565167-37-5 98%
    CK1δ-IN-6 (Compound 303) is a Casein kinase 1δ inhibitor. CK1δ-IN-6 is promising for research of Alzheimer's disease.
    CK1δ-IN-6
  • HY-169731
    RO27-3225 trifluoroacetate 1373926-49-8 98%
    RO27-3225 trifluoroacetate is a peptide agonist of melanocortin receptor 4 (MC4R) with neuroprotective and anti-inflammatory activity with an EC50 value of 1 nM, while 8 nM for MC1R. RO27-3225 trifluoroacetate reverses hemorrhagic shock, reduces brain edema, blood-brain barrier (BBB) permeability, and hippocampal IL-1β and TNF-α levels in a rat model of intra-abdominal hypertension induced by hemorrhagic shock and resuscitation.
    RO27-3225 trifluoroacetate
  • HY-169736
    JNK-IN-21 756849-36-2 98%
    JNK-IN-21 (Compound 62) is a JNK-1 inhibitor.
    JNK-IN-21
  • HY-169742
    Epibatidine 140111-52-0 98%
    Epibatidine is a α7nACh agonist with a Kd of 100 nM. Epibatidine can be used in the study of Alzheimer's, Parkinson's and schizophrenia.
    Epibatidine
  • HY-169786
    5-HT2A receptor agonist-5 2957888-63-8 98%
    5-HT2A receptor agonist-5 (compound I-3) is a potent 5-HT2A receptor agonist with a Ki value of 0.017 µM. 5-HT2A receptor agonist-5 shows antidepressant activity.
    5-HT2A receptor agonist-5
  • HY-169791
    ECPLA 2349367-50-4 98%
    ECPLA, a lysergamide lysergic acid diethylamidean (LSD) analog, is a potent 5-HT2A agonist (EC50 of 14.6 nM) for Gq-mediated calcium flux. ECPLA has high affinity for most serotonin receptors, α2-adrenoceptors, and D2-like dopamine receptors.
    ECPLA
  • HY-169808
    BOMA 540496-84-2 98%
    BOMA (Compound 7) is a potent and selective metabotropic glutamate receptor 5 (mGluR 5) antagonist with an IC50 value of 3 nM and an Ki value of 3 nM. BOMA is promising for research of various pain states, including acute, persistent and chronic pain, inflammatory pain and neuropathic pain.
    BOMA
  • HY-169814
    LU-25-077 221549-70-8 98%
    Lu 25-077 is a brain-penetrant and pharmacologically active N-demethyl metabolite of Lu 25-109 (HY-101586), a partial M1 agonist and M2/M3 antagonist. Lu 25-077 can be utilized in neurological research.
    LU-25-077
  • HY-169820
    CE-178253 benzenesulfonate 956246-95-0 98%
    CE-178253 benzenesulfonate is a CB1 antagonist with central nervous system activity.
    CE-178253 benzenesulfonate
  • HY-169824
    TRPML modulator 1 2171065-77-1 98%
    TRPML modulator 1 (compound A12) is a TRPML modulator that promotes autophagy. TRPML modulator 1 AC50 in the TFEB test is less than 2 mM.
    TRPML modulator 1
  • HY-169825
    (S)-PF-04995274 2170558-28-6 98%
    (S)-PF-04995274 is a partial agonist of the 5-hydroxytryptamine receptor 4 (5-HT4R) and is an isomer of PF-04995274 (HY-18137).
    (S)-PF-04995274
  • HY-169831
    HUP-55 3006795-68-9 98%
    HUP-55 is a prolyl endopeptidase inhibitor (IC50 = 5 nM). HUP-55 reduces the dimerization of α-synuclein in Neuro2a cells and induces autophagy (Autophagy) in HEK293 cells. It also decreases the increase in reactive oxygen species (ROS) production induced by hydrogen peroxide in SH-SY5Y cells at a concentration of 10 μM. In a mouse Parkinson’s disease model, HUP-55 (10 mg/kg) improves motor function (reduces the use frequency of the impaired paw) and decreases the levels of harmful oligomers of α-synuclein in the striatum caused by overexpression of α-synuclein.
    HUP-55
Cat. No. Product Name / Synonyms Application Reactivity